Skip to content
10-Q

Quarterly Report

Alaunos Therapeutics, Inc. TCRT

0001193125-26-227272

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 24.42M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.95M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.6M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.03M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$772K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $354K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.29M
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.06M
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.06M
Current Liabilities Q1 2026 · Mar 31, 2026 $595K
Current Liabilities Q1 2026 · Dec 31, 2025 $813K
Total Liabilities Q1 2026 · Mar 31, 2026 $595K
Total Liabilities Q1 2026 · Dec 31, 2025 $813K
Current Assets Q1 2026 · Mar 31, 2026 $970K
Current Assets Q1 2026 · Dec 31, 2025 $1.99M
Total Assets Q1 2026 · Mar 31, 2026 $1.88M
Total Assets Q1 2026 · Dec 31, 2025 $2.97M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.59
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.67
Eps Basic Q1 2026 · Mar 31, 2026 −$0.59
Eps Basic Q1 2026 · Mar 31, 2025 −$0.67
Sga Expense Q1 2026 · Mar 31, 2026 $585K
Sga Expense Q1 2026 · Mar 31, 2025 $747K
Rd Expense Q1 2026 · Mar 31, 2026 $427K
Rd Expense Q1 2026 · Mar 31, 2025 $347K
Net Income Q1 2026 · Mar 31, 2026 −$1.01M
Net Income Q1 2026 · Mar 31, 2025 −$1.07M
Operating Income Q1 2026 · Mar 31, 2026 −$1.01M
Operating Income Q1 2026 · Mar 31, 2025 −$1.09M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $2K